Bristol Myers Squibb stock: Wells Fargo cuts target to USD 60 from USD 65

Published on 10/21/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers sits 10.59 percent below USD 68.64 high. Bristol Myers Squibb stock costs EUR 54.46 on October 21, 2026, 0.37 percent below Xetra close.

Target and trading levels

Wells Fargo cut its Bristol Myers Squibb target from USD 65.00 to USD 60.00 on October 13, 2026.
Bristol Myers Squibb stock stood 10.59 percent below its USD 68.64 52-week high as of October 21, 2026.
Bristol Myers Squibb stock costs EUR 54.46 at Lang & Schwarz on October 21, 2026 at 3:22 p.m. CEST, 0.37 percent below the Xetra close of October 20, 2026.
Third-quarter results are scheduled for October 29, 2026 before the US market opens.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb cut its target to USD 60.00 from USD 65.00 in a Wells Fargo note dated October 13, 2026, while keeping an equal-weight rating, according to MarketBeat. Bristol Myers Squibb was trading at EUR 54.46 at Lang & Schwarz on October 21, 2026 at 3:22 p.m. CEST, 0.37 percent below the Xetra close of October 20, 2026 at EUR 54.66.

Revenue beat supports the setup

The latest reported quarter was the second quarter of 2026. Revenue reached USD 12.97 billion, up 5.70 percent from the same quarter a year earlier, while diluted earnings per share came to USD 1.62. MarketBeat reported that the quarter exceeded consensus, with earnings per share of USD 2.04 and revenue of USD 12.97 billion. The differing earnings-per-share figures reflect the source distinction between standardized financial data and the cited adjusted result.

Stock stays below its yearly high

At USD 61.37 on the NYSE at 9:30 a.m. ET on October 21, 2026, Bristol Myers Squibb was 10.59 percent below its 52-week high of USD 68.64 and 44.33 percent above its USD 42.52 low. The market capitalization was USD 125.4 billion, and the price-to-earnings ratio was 13.59 on the same date.

Valuation meets the October date

Wells Fargo's USD 60.00 target was 2.23 percent below the NYSE price of USD 61.37 on October 21, 2026. The next scheduled reporting date is October 29, 2026, before the US market opens, according to Fidelity.

Comparison with peers

Bristol Myers Squibb: down 0.37 percent, P/E 13.59, market capitalization USD 125.4 billion as of October 21, 2026.

Merck: down 0.80 percent, P/E 118.64, market capitalization USD 362.9 billion as of October 21, 2026.

Pfizer: down 0.70 percent, P/E 39.79, market capitalization USD 170.4 billion as of October 21, 2026.

What the target means for the stock

The Wells Fargo change places the cited target below the current NYSE price, while the euro quotation remains below the October 20 Xetra close. For investors, the October 29 reporting date is the next clearly defined company event.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.